Delving into the Latest Updates on TGRX-1942 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PTK7

Mechanism

PTK7 inhibitors(Protein-tyrosine kinase 7 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases

Active Indication

Non-Small Cell Lung CancerAdvanced Malignant Solid NeoplasmHematologic Neoplasms

Inactive Indication

Leukemia

Originator Organization

Shenzhen TargetRx, Inc.Startup

Active Organization

Shenzhen TargetRx, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的（1）剂量递增阶段：评估 TGRX-1942 片治疗晚期实体瘤受试者的安全性、耐受性，探索最大耐受剂量（MTD）以及Ⅱ期推荐剂量（RP2D）。（2）剂量扩展阶段及适应症扩展阶段：按照 RECIST 1.1 标准（和 RANO-BM 标准，2015，如适用）评估 TGRX-1942 片在不同晚期实体瘤中或不同基因突变状态下的有效性。

[Translation]

Main objectives (1) Dose escalation phase: To evaluate the safety and tolerability of TGRX-1942 tablets in the treatment of subjects with advanced solid tumors, and to explore the maximum tolerated dose (MTD) and the recommended dose for phase II (RP2D). (2) Dose expansion phase and indication expansion phase: According to the RECIST 1.1 standard (and RANO-BM standard, 2015, if applicable), evaluate the effectiveness of TGRX-1942 tablets in different advanced solid tumors or different gene mutation states.

Start Date-

Sponsor / Collaborator

Shenzhen TargetRx, Inc.Startup

NCT06484816 / Not yet recruitingPhase 1

A Dose Escalation and Expansion Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-1942 in Patients With Advanced Solid Tumor and/or Relapsed/Refractory Hematologic Malignancies

A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies

Start Date31 Jul 2024

Sponsor / Collaborator

Shenzhen TargetRx, Inc.Startup

[+1]

100 Clinical Results associated with TGRX-1942

Login to view more data

100 Translational Medicine associated with TGRX-1942

Login to view more data

100 Patents (Medical) associated with TGRX-1942

Login to view more data

100 Deals associated with TGRX-1942

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 1	-	Shenzhen TargetRx, Inc.Startup	31 Jul 2024
Advanced Malignant Solid Neoplasm	Phase 1	CN	Shenzhen TargetRx, Inc.Startup	11 Jun 2024
Hematologic Neoplasms	Phase 1	CN	Shenzhen TargetRx, Inc.Startup	11 Jun 2024
Leukemia	Preclinical	CN	Shenzhen TargetRx, Inc.Startup	-